Latham & Watkins represented Zentalis in the offering, and Cooley represented the underwriters. Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the pricing of an underwritten offering of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented NextGen Healthcare, while Davis Polk advised J.P. Morgan Securities LLC, the representative of the initial purchasers in the offering. NextGen Healthcare, Inc....
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the initial purchaser in the offering. Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development...
You must be a Standard 1 Year member to access this content.
